美迪西(688202.SH):已投入使用共計超過8.5萬平方米的研發辦公場地
格隆匯7月16日丨美迪西(688202.SH)近日在接待機構投資者調研時表示,公司已投入使用共計超過8.5萬平方米的研發辦公場地,分別位於張江高科技園區、川沙經濟園區、南匯美迪西新藥創新中心、杭州蕭山區以及在美國波士頓的研發中心。募投項目“藥物發現和藥學研究及申報平台的實驗室擴建項目”的主體結構已全面封頂並已申請驗收,“美迪西北上海生物醫藥研發創新產業基地項目”也已正式開工建設。未來將根據公司的戰略規劃和業務發展情況,穩步推進募投項目的建設。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.